Search

everythinglearnresearchcommunity

for

Search:↓

User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.

PP405 may revive dormant hair follicles, and DHT blockers like finasteride or dutasteride could maintain new hair. Combining PP405 with minoxidil might be optimal, but long-term effects and continuous use are uncertain.

The conversation is about the effectiveness of Fluridil (Eucapil) for hair loss compared to RU58841, with the original poster considering Fluridil a safer and potentially more effective alternative.

The user is exploring alternatives to hair transplants due to a weak donor area and is currently using finasteride, minoxidil, dermapen, low-level laser therapy, Nizoral shampoo, and a high-protein diet. They plan to switch to dutasteride and consider adding RU58841, while rejecting hair systems and considering a buzz cut.

GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.

DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

Current treatments for hair loss include finasteride, minoxidil, and derma rolling. New treatments like Breezula, PP405, and others are not expected until at least 2027 or later.

The conversation is about the anticipated release timeline for a hair loss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

Follicusan DP is discussed as a potential alternative to Minoxidil without side effects, but information is scarce. It is noted to be of German origin and details on its mechanism are limited.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

A 20-year-old used finasteride, minoxidil foam, and micro-needling for hair regrowth, experiencing initial shedding but later improvement with minimal side effects. They are happy with the results and seek advice on additional products like rosemary oil for scalp health.

User reported initial hair regrowth with 0.25 mg finasteride taken four times a week, experiencing a second shedding phase, and no side effects. They also mentioned using RU58841 without success and plan to stop after a year.

The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.

The conversation discusses the effects of B5 (Pantothenic acid), B7 (Biotin), and B12 on hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

Significant hair regrowth was achieved using a topical combination of 0.3% finasteride and 6% minoxidil, with weekly dermastamping and ketoconazole shampoo, without side effects. Others suggested additional treatments like red light therapy and PRP.

A user experienced no hair regrowth after using oral minoxidil, topical finasteride, minoxidil, and tretinoin, and reported side effects from oral finasteride. They are considering switching to dutasteride or using hair fibers for better results.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

Hair loss treatment should target dermal white adipose tissue (DWAT) to restore hair follicles. Potential remedies include tocopherol (vitamin E), botox, rosiglitazone, niacin, kojyl cinnamate esters, and ADP355.

A sugar gel has been found to aid hair regrowth, similar to minoxidil, and may improve blood supply to hair follicles. Some users report success with homemade versions, though side effects like dizziness have been noted.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Alfatradiol is suggested as another potential solution.

Users discuss potential game-changing hair loss treatments in the next 10 years. Some mention KX-826, SCUBE3, and stem cells as promising options, while others express doubt due to past disappointments and lack of focused research.

A 19-year-old diagnosed with AGA was refused finasteride by a dermatologist who cited fertility concerns and prescribed minoxidil, vitamins, and shampoos instead. The user is unsure about using minoxidil and considers finding another dermatologist.

The user received a Fagron TrichoTest indicating that Finasteride, Dutasteride, and Minoxidil are not effective for them, recommending Latanoprost, Spironolactone, IGrantine-F1 TM, and Trichoxidil instead. Other users expressed skepticism about the test's validity and suggested sticking with proven treatments like Finasteride and Dutasteride.

A person had a hair transplant using FUE with 4150 grafts after a previous FUT with 2000 grafts and is now using Dutasteride and oral Minoxidil. They are concerned about hair gaps on the side, questioning if they are a result of the transplant and if they are temporary.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.